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tA key feature in Huntington disease (HD) is the accumulation of mutant Huntingtin (HTT)
protein, which may be regulated by posttranslational modifications. Here, we define the primary
sites of SUMO modification in the amino-terminal domain of HTT, show modification
downstream of this domain, and demonstrate that HTT is modified by the stress-inducible
SUMO-2. A systematic study of E3 SUMO ligases demonstrates that PIAS1 is an E3 SUMO
ligase for both HTT SUMO-1 and SUMO-2 modification and that reduction of dPIAS in a mutant
HTT Drosophila model is protective. SUMO-2 modification regulates accumulation of insoluble
HTT in HeLa cells in a manner that mimics proteasome inhibition and can be modulated by
overexpression and acute knockdown of PIAS1. Finally, the accumulation of SUMO-2-modified
proteins in the insoluble fraction of HD postmortem striata implicates SUMO-2 modification in
the age-related pathogenic accumulation of mutant HTT and other cellular proteins that occurs
during HD progression.
INTRODUCTION
Huntington disease (HD) is caused by the expansion of a CAG repeat within the HD gene
and the corresponding poly-glutamine track within the Huntingtin (HTT) protein
(MacDonald et al., 1993). Symptoms include movement abnormalities, psychiatric
symptoms, and cognitive deficits with accompanying degeneration of medium spiny neurons
in striatum and loss of cortical volume (Ross and Tabrizi, 2011). Posttranslational
modifications modulate protein function, and HTT is subject to multiple functionally
relevant modifications including SUMOylation, ubiquitination, acetylation, palmitoylation,
and phosphorylation (for review, see Ehrnhoefer et al., 2011; Pennuto et al., 2009). We
previously demonstrated that a fragment of mutant HTT is modified by Small Ubiquitin-like
MOdifier 1 (SUMO-1), and genetic reduction of SUMO in Drosophila-expressing mutant
HTT exon 1 is protective (Steffan et al., 2004). SUMO-1 modification of mutant HTT in
cells was also associated with increased toxicity and decreased aggregation by the striatal
enriched small guanine nucleotide-binding protein Rhes (Subramaniam et al., 2009). SUMO
modification is also implicated in Alzheimer’s disease (AD), Parkinson’s disease (PD), and
amyotrophic lateral sclerosis (ALS), as well as other CAG repeat diseases (SBMA, DRPLA,
SCA1, and SCA7) (for review, see Krumova and Weishaupt, 2013; La Spada and Taylor,
2010; Wilkinson et al., 2010). Although this modification is linked to pathogenesis, the
precise mechanisms involved have not yet been elucidated.
SUMO modification is the covalent attachment of SUMO to specific lysine residues within a
target protein and regulates key processes involved in normal cellular function, including
subcellular localization, protein stability, transcriptional regulation, and interaction
properties of SUMO-modified proteins with their cellular targets (Cubeñas-Potts and
Matunis, 2013; Gareau and Lima, 2010). Although highly transient, the effects of this
modification are long lasting (Johnson, 2004). Four different forms, SUMO-1–SUMO-4,
exist in mammals. SUMO-2 and SUMO-3 are nearly identical (97% identity) and often
referred to as one protein (SUMO-2/SUMO-3) (Gareau and Lima, 2010; Johnson, 2004),
and SUMO-4 is found only in a precursor form (Bohren et al., 2004). The SUMOylation
pathway involves a cascade of enzymes, similar to ubiquitination, with a single E1-
activating enzyme (SAE1/UBA2), a single E2-conjugating enzyme (UBC9), multiple E3-
ligating enzymes (Protein Inhibitors of Activated STAT [PIAS], PC2, MMS21, and
RanBP2), which provide substrate specificity, and multiple pro-teases (SENPs) that both
cleave the SUMO moiety from target proteins and process SUMO itself (Figure 1A). Given
that SUMOylation is implicated in HD and other neurodegenerative diseases, identification
of the E3s responsible for HTT modification may provide insight into mechanisms
underlying HD and provide novel therapeutic targets.
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tHere, we systematically evaluated the enzymatic machinery involved in HTT SUMO
modification and report for the first time that HTT is modified by SUMO-2 and that PIAS1
functions as a HTT SUMO E3 ligase. This modification may serve more than one function
because longer HTT polypeptides, both wild-type (WT) and mutant, are SUMO modified
downstream of exon 1. SUMO-2 overexpression causes mutant HTT to accumulate in cells.
In HD postmortem striatum, SUMO-2-modified proteins accumulate in the insoluble
fraction, suggesting that this modification is relevant in vivo to HD. Further validating the
potential in vivo relevance for SUMO modification pathways in HD, genetic reduction of
dPIAS in Drosophila expressing expanded repeat HTT is neuroprotective. Taken together,
these results provide a rationale for targeting SUMO-2 and PIAS1 as novel therapeutic
targets for HD.
RESULTS
HTTex1p Lys 6 and Lys 9 Are the Primary Sites of SUMO Modification
We previously showed that truncated HTT (Httex1p) is SUMO-1 modified in cells and that
Lys 6 (K6) and Lys 9 (K9) may represent primary sites for modification based on the
absence of SUMO modification upon mutagenesis of target lysines (Steffan et al., 2004).
From these studies, it was not clear which lysines are preferentially SUMO modified. Based
on SUMO prediction software (SUMOplot, Abgent), the lysines in HTTex1p (Figure 1A) do
not fall within a classic SUMO consensus sequence but, rather, are low-probability SUMO
sites or not predicted (Figure 5A). However, classic SUMO consensus sequences are neither
necessary nor sufficient for determining SUMO modification of a protein. To directly
determine which of the three N-terminal lysines (K6, K9, or K15) are preferentially SUMO
modified, HTTex1p and lysine mutants, mutated singly and in combination, were purified
and analyzed using an in vitro SUMO modification system followed by mass spectrometry
analysis. SUMO-1 (t95R) was used based on ease of detection of mono-SUMO
modification, and to minimize the confounding effect of aggregation, unexpanded HTTex1p
(25Q) constructs were used. When K6 and K9 were mutated singly to arginine (K6R, K9R),
SUMO modification is reduced compared to WT, but when K6 and K9 (K6,9R) are mutated
together, SUMO modification is greatly reduced, similar to the three lysine mutants (Figure
1B), suggesting that K6 and K9 are the major target sites. Mass spectrometry analysis
confirmed that K6 and K9 are indeed the primary sites of SUMO modification (Figure S1).
HTTex1p is subject to other posttranslational modifications such as ubiquitination and
phosphorylation (Ehrnhoefer et al., 2011; Zheng and Diamond, 2012). Because (1)
phosphorylation modulates SUMO modification of cellular proteins, (2) mimicking
phosphorylation of serines 13 and 16 (S13 and S16, respectively) in expanded repeat
HTTex1p (97QP) regulates SUMO-1 modification in cells (Thompson et al., 2009), and (3)
this modification is relevant in vivo (Gu et al., 2009), we evaluated SUMO modification of
WT HTTex1p (25Q) in the context of a HTT phosphomimic S13,16D in vitro. SUMO
modification of the phosphomimetic HTT (25Q) was equal to or more rapid than for WT
HTT control (Figure 1B); mass spectrometry analysis revealed that SUMO modification of
the S13,16D phosphomimic is restricted to K6 (Figure S1). These results suggest that both
in vitro and in cells, other posttranslational modifications, including phosphorylation, may
influence SUMO modification of HTT.
PIAS and SUMO Modification Proteins Are Highly Expressed in Mouse Brain
Because SUMO E3 ligases provide specificity in targeting proteins where a modified lysine
does not fall within a consensus site (Gareau and Lima, 2010), such as HTT, identifying the
E3 ligase(s) that promotes HTT SUMOylation may be key to identifying therapeutic targets
that regulate this modification. Based on the fact that PIASy was identified as a HTT-
O’Rourke et al. Page 3
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tinteracting protein in a yeast two-hybrid (Y2H) screen (Goehler et al., 2004), we evaluated
whether PIAS proteins could function as HTT E3 ligases. In humans, the PIAS family
consists of four members: PIAS1, PIASx (xα and xβ), PIAS3, and PIASy. Originally
identified as PIAS (Shuai and Liu, 2005), the PIAS proteins are involved in regulation of
transcription, immune responses, cytokine signaling, and E3 ligase activity (Liu and Shuai,
2008; Rytinki et al., 2009). As E3 ligases, they enhance SUMOylation of a number of
different proteins, and multiple PIAS proteins can sometimes act as E3 ligases for the same
substrate (Schmidt and Müller, 2002).
To first establish that SUMO modification enzymes are present in brain regions relevant to
HD, expression of SUMO-related proteins was quantified in mouse striatum and cortex
using quantitative RT-PCR (qRT-PCR). SUMO-1, SUMO-2, PIAS, and SENP mRNAs are
all expressed in WT cortex and striatum. Within each region, PIASx is most highly
expressed, followed by PIAS1, with PIAS3 and PIASy having similar expression profiles
(Figure 2A). This suggests that any PIAS could potentially serve as a HTT E3 SUMO ligase
based on its expression in vivo. The SENP proteins are also expressed in the brain, with
SENP6 most highly expressed followed by SENP2 and SENP3, and finally SENP1 (Figure
2A). SUMO-1 and SUMO-2 are expressed in mouse brain at relatively high levels. These
data demonstrate that the SUMO machinery is present in relevant brain regions.
To determine if these SUMO-related genes show expanded repeat HTT-dependent
alterations in expression patterns, each was quantified in WT and R6/2 mouse cortex and
striatum at 4, 8, and 12 weeks. R6/2 mice express a truncated HTT fragment (exon 1 with
~150Qs) and show very rapid HD-like disease progression with onset by approximately 6
weeks, highly penetrant phenotypes at 8 weeks, and end-stage disease by 12 weeks
(Mangiarini et al., 1996). At 4 and 8 weeks, some dysregulation begins to occur (Figures
S2A and S2B), and by 12 weeks, there are statistically significant increases of SENP1,
SENP3, and SUMO-1 in R6/2 cortex and of SENP1, SENP6, PIAS3, SUMO-1, and SUMO-2
in R6/2 striatum (Figures 2B and 2C), suggesting that in vivo SUMO-modifying pathways
may be perturbed in HD. The increases in SUMO-1 and SUMO-2 specifically in striatum,
the region of greatest vulnerability to neurodegeneration, were particularly noteworthy. A
similar pattern of increased SUMO-2 in R6/2 striatum but not cortex was also observed at
the protein level (Figures 2D and 2E), suggesting a SUMO-2-selective response in striatum.
RNA was also isolated from dissected brain regions of BACHD mice (Gray et al., 2008) that
express full-length human HTT as a BAC transgene with 97Qs and show progressive
disease over a longer time course. SUMO-1 and SUMO-2 expression was similarly increased
in BACHD striatal samples at 14 months (Figure S2C), a time when disease phenotypes are
evident, and SUMO-2 is increased in N171 mouse striatum at 12 weeks compared to 6
weeks (Jia et al., 2012). The progressive nature of these changes, with the most robust
observed at late disease stages, is consistent with the concept of early changes in protein
homeostasis systems (Schipper-Krom et al., 2012) with later profound disruption of the
SUMO network at the gene expression and protein level. Taken together, the most consistent
change in fragment and full-length mutant HTT mouse models is upregulation of SUMO,
suggesting that this pathway may be dysregulated in vivo.
HTTex1p Is Modified by Both SUMO-1 and SUMO-2
Modification by SUMO-2 is unique in its capacity to be induced by cellular stress (Saitoh
and Hinchey, 2000). Based on our previous data that the stress-inducible kinase IKK can
activate phosphorylation of HTT S13 and S16 and increase polySUMOylation of 97QP
HTTex1p (Thompson et al., 2009), and given that oxidative stress and other cellular
stressors are implicated in HD (Browne and Beal, 2006), we investigated whether SUMO-2
can modify HTT. A cell-based SUMOylation assay was optimized to visualize and quantify
O’Rourke et al. Page 4
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tSUMO modification (Figure S3A; Extended Experimental Procedures), which for
endogenous proteins, is a highly dynamic process, and only low levels of modification are
typically observed for an individual protein at any given time (Johnson, 2004). Expanded
repeat HTTex1p (46QP) with a C-terminal epitope tag (46QP-H4) was cotransfected with
SUMO-1 (GFP-SUMO-1) or SUMO-2 (GFP-SUMO-2) and then purified under denaturing
conditions using magnetic nickel beads (Ni-NTA). SUMO-1 and SUMO-2 can both modify
HTTex1p, and when the lysines (K6, K9, and K15) are mutated to arginine (3R), SUMO
modification cannot be detected (Figure 3A). An unusual laddering below control HTT in
the presence of SUMO-2, but not in the presence of lysine mutants, is observed for this
construct; however, the laddering is not detected by anti-GFP, and its significance is not
clear.
PIAS1 Is a Candidate SUMO E3 Ligase for HTT
Each of the PIAS proteins was evaluated for its ability to enhance SUMO modification of
HTT, and the ratio of SUMO-modified HTT versus purified HTT was quantified using a
western blot imaging system (Odyssey Imager; LI-COR). Because the PIAS proteins are
regulators of transcription, like SUMO, and can act as coactivators and corepressors in
addition to their E3 ligase activity (Rytinki et al., 2009), one-tenth mycactin under a CMV-
based promoter was cotransfected to account for transcriptional effects (Thompson et al.,
2009; Figure S3A). To control for differences in protein loading due to denaturing
conditions precluding protein assays, each membrane was stained with a reversible protein
stain (MEMCode). Finally, to control for differential HTT expression, 10% of each sample
was trichloracetic acid (TCA) precipitated and subjected to western analysis. To
demonstrate that the modified form of HTT does indeed represent SUMO-modified HTT,
SUMO-1 was coexpressed in its mature, processed form (SUMO-1-GG) together with each
of the SUMO isopeptidase SENPs (SENP1, SENP2, SENP3, SENP5, and SENP6) to show
elimination by isopeptidases. SENP1, SENP2, and SENP6 each catalyzed removal of
SUMO-1 from HTT, whereas SENP3 and SENP5 had no effect (Figure 3B), providing
validation that the shift in protein mobility represents SUMO-modified HTT and suggesting
selectivity of isopeptidase action.
To evaluate each PIAS protein for the ability to enhance HTT SUMO modification, 46QP-
H4 was coexpressed with SUMO-1 (GFP-SUMO-1) and each of the PIAS proteins (PIAS1,
PIASxα, PIASxβ, PIAS3, and PIASy). HTT is readily modified by SUMO-1 (Steffan et al.,
2004) and (Figure 3A) at saturating levels of SUMO-1. In order to detect enhancement of
SUMO-1 modification, a titration was performed to determine the SUMO-1 concentration at
which modification of HTT was barely detectable (Figure 3C) and the addition of a relevant
E3 ligase could increase HTT SUMO modification (Stankovic-Valentin et al., 2007). PIAS1
repeatedly enhanced SUMO-1 modification of HTTex1p (Figure 4A, representative figure),
as did Rhes as previously reported (Figure S3B).
We next investigated whether SUMO-2 modification of HTT is also sensitive to the addition
of an E3 ligase. Because this modification is more difficult to visualize under basal
conditions, limiting SUMO-2 levels was not necessary. SUMO-2 was cotransfected with
individual PIAS cDNAs, and PIAS1 was also most effective at enhancing SUMO-2
modification of HTT (Figure 4B, representative figure). In this assay, Rhes did not enhance
the formation of a SUMO2-HTT species (Figure S3C).
Consistent with its role as an E3 SUMO ligase and the underlying rationale that direct
interactions between E3 ligases and targets can promote SUMO modification, PIAS1 was
evaluated for its ability to bind to HTT fragments in vitro. Using GST pull-down assays with
HTT exon 1-encoding polypeptides, both normal range (20QP) and expanded repeat
HTTex1p(51QP) interact strongly with PIAS1 (7.75% and 7%, respectively) (Figure 4C).
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tAs controls, protein lacking the protein-interacting proline-rich domain of Htt (20Q and
51Q) or expressing the proline-rich region alone showed greatly reduced interactions. These
results suggest that a direct interaction between PIAS1 and HTTex1p may facilitate SUMO
modification.
Longer HTT Fragments Are SUMOylated
A potentially critical and initiating cleavage event occurs at a caspase-6 cleavage site of
HTT (Graham et al., 2006), creating a polypeptide of 586 amino acids (HTT 586 aa). Using
bio-informatic tools (SUMOplot; Abgent), five additional lysines downstream of HTTex1p
are predicted to be SUMO modification sites of high (two lysines) or lower (three lysines)
probability (Figure 5A). Of interest, further analysis of the 586 aa fragment reveals up to 13
potential overlapping SUMO-interacting motifs (SIMs) within this region depending upon
consensus sequence designation (Figure 5A) (Tatham et al., 2008). SIMs are noncovalent
interactions that may enhance SUMOylation of the SIM-containing proteins themselves
(Blomster et al., 2010). Therefore, the SUMO and SIMs in HTT may work together to
regulate HTT SUMOylation.
To determine if longer HTT fragments are SUMOylated independently of the lysines within
the first 17 aa, HTT 586 aa containing either an unexpanded (25Q-586 aa) or expanded
polyQ repeat (137Q-586 aa) was coexpressed with SUMO-1 (Figure 5B) because this
modification should be detected under basal conditions. As a control, HTT 586 aa constructs
with K6,9,15R mutations that diminish SUMO modification within the first 17 aa were
tested. Immunoprecipitated HTTex1p (46QP-H4) is monoSUMOylated by SUMO-1 (Figure
5B), but the 3R mutant form is not modified as expected. However, other lysines
downstream of this amino-terminal domain can also be SUMOylated because SUMO-1
modification is observed even in the presence of the K6,9,15R mutation in either its
expanded or unexpanded forms.
PIAS1 Increases SUMO-2 Modification of HTT 586 aa
SUMO-2 modification of HTT 586 aa is not detected in the absence of external stimuli
(Figure 5E); therefore, longer HTT fragments were evaluated for SUMO-2 modification in
the presence of an E3-SUMO ligase. Potential interactions between longer HTT fragments
and E3 SUMO ligases were first investigated using a large-scale Y2H screen. Here, the 586
aa fragment of HTT was used as bait, and PIAS1 emerged as the single E3 SUMO ligase
interaction partner (Figure 5C), supporting its relevance even for longer HTT polypeptides.
Previously identified interactors were also tested in this system and confirmed, including
HIP2 and GIT1 (Goehler et al., 2004). To further validate this interaction in vitro,
coimmunoprecipitation of HTT from cell lysates transfected with HTT (25Q-586) and
PIAS1 with or without cotransfected SUMO-1 was tested. PIAS1 binds both transfected
HTT (586 aa) and full-length endogenous HTT based on PIAS1 detection even in the
absence of exogenous HTT 586 overexpression (Figure 5D). SUMO-2 modification of
longer HTT polypeptides was therefore tested in the presence of PIAS1. Based on in vitro
results (Figure 1B) and because SUMO-2 is stress inducible similar to the signal
transduction cascades that modulate HTT phosphorylation, S13, 16D phosphomimic
polypeptides were also tested. Expanded repeat HTT 586 aa fragments are SUMO-2
modified in the presence of PIAS1, and this modification is enhanced by mimicking
phosphorylation (S13, 16D-586 aa) for both expanded and unexpanded HTT 586 aa (Figures
5E and 5F).
SUMO-2 Promotes Accumulation of Insoluble Mutant HTT
Emerging data suggest that SUMOylation may influence aggregation and accumulation of
aggregation-prone neurodegenerative disease proteins (Kim et al., 2011; Tatham et al.,
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t2011). To address the functional consequences of SUMO modification of mutant HTT on
disease, the involvement of SUMO-1 and SUMO-2 modification on the formation of
insoluble HTT species was evaluated in HeLa cells, where SUMO modification systems are
highly active. Our previous studies evaluated visible inclusion formation and levels of
soluble mutant HTT and showed that fusion of SUMO to the HTTex1p N terminus
promoted stabilization of HTTex1p (Steffan et al., 2004). However, we and others have
since identified the HTTex1p N terminus as an important mediator of aggregation,
localization, and protein stability (Atwal and Truant, 2008; Rockabrand et al., 2007;
Sivanandam et al., 2011; Thompson et al., 2009; Zheng et al., 2013), which may have been
masked by the presence of the SUMO moiety. SUMO-1 also decreased mutant HTT
aggregation in the presence of Rhes and increased toxicity in cells (Subramaniam et al.,
2009). In each case, only SUMO-1 was evaluated.
For HD, the process of aggregation and specific aggregation intermediates are likely to be
critical to pathogenesis. Using a centrifugation protocol published for α-synuclein (Kim et
al., 2011), lysates were separated into detergent-soluble and detergent-insoluble fractions.
The detergent-soluble fraction contains monomeric HTT, which includes overexpressed
mutant HTTex1p (97Q) and endogenous full-length HTT (indicated by arrows in Figure 6A,
SOLUBLE fraction). In contrast, the detergent-insoluble fraction contains only high
molecular weight (HMW) HTT in the samples containing 97Q-HTTex1p (Figure 6A,
INSOLUBLE fraction), which are likely multimers or potentially oligomers of soluble HTT.
MG132 is a proteasomal inhibitor that causes the accumulation of mutant HTT in cells (Lee
and Goldberg, 1998). To investigate the relationship between proteasomal degradation and
SUMO modification and to analyze levels of soluble and insoluble HTT species in the
presence of SUMO-1 and SUMO-2, HeLa cells were transiently transfected with 97Q-
HTTex1p and treated with MG132 (5 μM). Treatment with MG132 causes a robust increase
in HMW mutant HTT in the insoluble fraction (Figure 6A), with accumulation of ubiquitin-
modified cellular proteins (data not shown). In contrast, soluble, monomeric HTT levels are
maintained or slightly decreased (Figure 6A), supporting the concept that impairment of
proteasomal function increases levels of aggregating HTT. Immunoprecipitation was
performed to increase HTT detection. Addition of SUMO-1 had little to no additional effect
on soluble HTT or insoluble HMW HTT levels (Figures 6B and 6C). However, the addition
of SUMO-2 caused an increase in insoluble HTT (Figures 6B and 6C) that was comparable
to proteasome inhibition. This effect is not augmented by combined SUMO-2 expression
and proteasome inhibition, suggesting that SUMO-2 modulates accumulation and
aggregation of mutant HTT in a manner that mimics proteasome inhibition. This regulation
of insoluble HTT levels by SUMO-2 is dose dependent. When cells were treated with
increasing amounts of SUMO-2, verified by increasing levels of mono-SUMO-2 by western
analysis (Figure 6D, boxed in first panel), increasing levels of HMW HTT were observed,
whereas monomeric levels showed a corresponding decrease in the insoluble fraction,
potentially reflecting insoluble monomeric HTT levels.
Because SUMO-2 modulates HMW HTT species and SUMO-2 modification of HTT
appears to require the presence of a SUMO E3 ligase, we tested whether PIAS1 alone can
modulate mutant HTT accumulation. When PIAS1 was over-expressed in the presence of
expanded repeat HTT with 97Qs, the detergent-insoluble HTT HMW “oligomeric” species
increased, whereas soluble HTT appeared to be unaffected (Figure 7A), and a reduction of
the HMW oligomeric HTT species is observed following PIAS1 acute knockdown (Figure
7B). Taken together, these data demonstrate that PIAS1 can regulate the accumulation of
insoluble HMW HTT polypeptide species, suggesting that modulation of PIAS1 may
influence pathogenesis in HD.
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tGenetic Reduction of Su(-var)2-10 Is Neuroprotective in Mutant HTTex1p-Expressing
Drosophila
To validate the potential involvement of PIAS proteins in HD pathogenesis in vivo, the
single Drosophila PIAS protein, Su(-var)2-10 (dPIAS) (Hari et al., 2001), was evaluated for
its effect on HD-like phenotypes in a fly model (Steffan et al., 2001). When expressed in all
neurons from embryogenesis on, expanded repeat HTTex1p (93Q) causes a progressive loss
of visible rhabdomeres (photoreceptor neurons in the eye) (Marsh and Thompson, 2006) and
a decrease in the number of flies that eclose from the pupal case as adult flies (Figure 7C).
When expressed in a background of heterozygous genetic reduction of dPIAS, the number of
visible photoreceptor neurons and survival (eclosion) are both increased (Figure 7C). The
observed neuroprotection is not simply a consequence of decreased transgene expression
based on analysis of HTT RNA by qPCR (data not shown). These results are consistent with
our previous observations showing that reduction of Drosophila SUMO (smt3) was
protective in this same model (Steffan et al., 2004).
Insoluble SUMO-2-Modified Proteins Are Increased in Human HD Brain
To investigate whether SUMO-modified proteins accumulate in HD brain tissue compared
to control subjects and whether SUMO-1 or SUMO-2 has selective effects, postmortem
striata from three control and three HD brains were evaluated. Each of the HD subjects
displayed a remarkable accumulation of SUMO-2-modified protein compared to controls in
insoluble fractions (Figure 7D). To a lesser extent, accumulation of SUMO-1 is also
observed. Differences in the levels of SUMO-2-modified protein do not correlate with
ubiquitin reactivity in control and HD brain fractions but, rather, appear to be specific for
SUMO. Although we cannot conclude from these data that the increased SUMO-2 reactivity
represents an increase in mutant HTT SUMO-2 modification per se, a HTT antibody raised
against aa 115–129 shows a similar pattern of increased HMW HTT species in HD samples
compared to controls (Figure 7D), suggesting that HTT is included in the proteins that
accumulate in HD striata. Taken together, these results support SUMO-2 relevance in HD
pathology and that SUMO-modifying enzymes may be valid therapeutic targets.
DISCUSSION
SUMO modification contributes to an impressive array of regulatory mechanisms that have
critical biological functions (Bruderer et al., 2011). In turn, dysregulation of this cellular
process is implicated in diseases ranging from cancer to neurological disease (Gareau and
Lima, 2010). Although SUMO modification is transient, downstream consequences are long
lasting and impact processes such as protein folding, subcellular localization, stability,
transcriptional regulation, and protein activity (Geiss-Friedlander and Melchior, 2007), all of
which are affected in HD (Zheng and Diamond, 2012). Implicating a role in
neurodegenerative diseases, a growing number of causative neurodegenerative disease
proteins either colocalize with SUMO molecules or are target proteins for SUMO
modification (for review, see Krumova and Weishaupt, 2013; Wilkinson et al., 2010). To
date, the primary mechanisms involve altered solubility of or visible inclusion formation by
these disease proteins, with ensuing protective (SBMA), deleterious (SCA7), or mixed
effects (α-synuclein), depending on the protein context and form of SUMO tested. Enzymes
involved in these processes, such as Rhes, are beginning to emerge (Oh et al., 2011;
Subramaniam et al., 2009).
Here, we demonstrate that SUMO-2 modification of HTT, a stress-responsive modification
pathway not previously investigated for HTT, regulates the accumulation of insoluble
mutant HTT. This SUMO form is consistently upregulated in striata from several HD mouse
models, at a stage of disease anticipated to display significant dysregulation of protein
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thomeostasis network components. Furthermore, PIAS1, which selectively enhances HTT
SUMO-1 and SUMO-2 modification and is expressed in brain, is integral to this
accumulation. The functional relevance of these findings is further validated by (1) the
neuroprotection observed upon reduction of the single Drosophila PIAS (dPIAS), which is
most similar to PIAS1 (Hari et al., 2001), in flies expressing a mutant fragment of HTT, and
(2) the profound accumulation of SUMO-2-modified HMW protein in human HD brain. The
finding that the stress-responsive SUMO-2 is likely most relevant to HD pathogenesis over
basal SUMO-1 modification by regulating the accumulation of HMW and likely poly-
SUMOylated protein is consistent with the prevailing literature that chronic expression of
mutant HTT causes cellular stress, including oxidative stress (Turner and Schapira, 2010).
This cellular stress, which is likely progressive and could therefore promote stress
responses, including SUMO-2 modification, could then contribute to disease. Validation of
SUMO-2 involvement in response to neuronal stressors has recently emerged in several
systems, including APP overexpression in AD mice (McMillan et al., 2011), transient
cerebral ischemia in brains of ground squirrels (Lee et al., 2012), and transient ischemia in
cells (Yang et al., 2012), in some cases, promoting a neuroprotective response to ischemic
stress (Datwyler et al., 2011).
We previously reported that mimicking phosphorylation of S13 and S16 reduces
monoSUMOylation and increases polySUMOylation of mHTTex1p with a highly expanded
97Q repeat (Thompson et al., 2009). Here, we confirm that K6 and K9 within the first 17 aa
domain are indeed SUMO-1 modification sites even though these lysines do not lie within
classic SUMO consensus sequences. Intriguingly, SUMO-1 is conjugated to K6 and K9
equivalently in the absence of other modifications, whereas phosphomimetic substitutions of
S13 and S16 appear to block SUMO modification on K9 or promote SUMO-1 modification
on K6, which may be significant to regulation of other HTT modifications, such as K9
acetylation. In cells, mimicking phosphorylation at these sites enhances SUMO-2
modification in the presence of a relevant E3 SUMO ligase. Given that phosphorylation of
HTT is responsive to inflammatory cues (Thompson et al., 2009), that PIAS1 is involved in
immune function, and that inflammation is increased in HD (Björkqvist et al., 2009;
Khoshnan et al., 2004), it is likely that SUMO-2 modification is also responsive to
inflammatory cues that appear early in HD.
A key feature in HD is the accumulation of mutant HTT fragments containing the polyQ
expansion (Landles et al., 2010). WT and mutant HTT can be cleaved by caspases, calpains,
and aspartyl proteases to form N-terminal fragments (Warby et al., 2008), which become
toxic when in the context of the expanded polyglutamine repeat. Studies in mice expressing
a caspase-6-resistant form of mutant HTT suggest that HTT proteolysis specifically at 586
may be critical to HD pathogenesis (Graham et al., 2006; Warby et al., 2009), and
overexpression of transgenic-expanded repeat HTT 586 supports potential toxicity of this
fragment (Waldron-Roby et al., 2012). Analysis of longer polyQ polypeptides revealed that
unexpanded and expanded HTT 586 fragments are SUMOylated downstream of HTTex1p.
The caspase-6 cleavage fragment of HTT (586 aa) has five predicted SUMOylation sites C-
terminal to exon 1, with potentially greater than 13 overlapping SIMs within this region,
depending on the SIM evaluated. SIMs are noncovalent protein-protein interactions that
have recently emerged as having critical regulatory properties (Gareau and Lima, 2010). For
example, the ubiquitin ligase RNF4 has multiple SIMs that recognize polySUMO-2 chains
and ubiquitinate them for degradation by the proteasome (Geoffroy and Hay, 2009; Tatham
et al., 2008). Indeed, these SIMs may be important signal transduction inducers downstream
of polySUMOylation events (Sun and Hunter, 2012). SIMs within target proteins can also
enhance their SUMO modification and are found within several E3-SUMO ligases,
including PIAS1 (Gareau and Lima, 2010). The implications of these multiple SIMs in HTT
are not yet clear; however, we are actively pursuing this area of investigation.
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tThe interplay between SUMO-2 and proteasome inhibition is consistent with recent
proteomic analysis of extracts from HeLa cells treated with MG132 to identify SUMO-2-
modified proteins (Tatham et al., 2011). In these studies, all SUMO paralogs accumulated
upon treatment with MG132; however the greatest response exhibited was by SUMO-2,
suggesting that SUMO modification of cellular proteins is not only involved in regulating
proteostasis of unfolded and misfolded proteins within a cell but may in fact represent a
response to the presence of misfolded or oligomerized proteins, such as mutant HTT, and be
involved in protein clearance mechanisms. This hypothesis is supported by studies showing
that the presence of mutant HTT polypeptide alone in C. elegans can cause the misfolding
and inactivation of temperature-sensitive mutant proteins to a similar degree as heat shock
(Gidalevitz et al., 2006). These findings suggested that mutant HTT protein expression is
sufficient to impact the protein homeostatic network and relevant to the work described
here, accumulation of SUMO-2-modified cellular proteins. Furthermore, when the
production of misfolded proteins exceeds the capacity of the chaperone and UPS systems,
mimicked here by proteasome/cathepsin inhibition by MG132, then these proteins may be
targeted for degradation by autophagy, which also becomes impaired late in disease. As
protein clearance mechanisms become impaired upon aging, modified proteins normally
targeted for degradation by post-translational modification, such as phosphorylation and
acetylation, may accumulate and take on toxic functions. Supporting this concept,
proteasome inhibition promoted formation of aggregates containing SUMO-modified α-
synuclein (Kim et al., 2011).
In summary, the work presented here supports a general mechanism in HD whereby the
chronic expression of expanded repeat HTT promotes general protein misfolding and
initiation of stress response pathways that promote SUMO-2 modification of HTT,
progressively resulting in accumulation of insoluble and HMW species that may be a
reflection of ongoing pathogenesis. In addition, loss of normal HTT functions may also
contribute to the accumulation of SUMOylated proteins (Steffan, 2010). Initially, SUMO-2
modification and polySUMOylation are likely to facilitate normal cellular clearance
mechanisms with integration between SUMOylation and ubiquitination and serve in a
neuroprotective capacity; however, these are likely to become toxic as pathways become
impaired and these species accumulate and cause further disruption of overall cellular
protein homeostasis, reflected here by increased expression and level of SUMO-2 and other
SUMO modification cellular components. This is demonstrated by the accumulation of
SUMO-2 protein in a HMW insoluble fraction from human HD striatum, the region most
profoundly affected in HD. We further identify a HTT E3-SUMO ligase, PIAS1, which is
expressed in relevant brain regions and appears to have a pivotal role in the regulation of
SUMO-2-modified HTT, providing a novel and selective therapeutic target.
EXPERIMENTAL PROCEDURES
Plasmids
Plasmid generation is described in the Supplemental Information.
siRNA
siRNA against PIAS1 and a nontargeting control were purchased from Dharmacon (Thermo
Scientific) and include PIAS1-ON-TARGETplus SMARTpool (L-008167-00-0005), Human
PIAS1, NM_016166, and ON-TARGETplus Non-targeting siRNA #1 D-001810-01-20.
Primary Antibodies
Anti-HTT (Enzo Life Sciences) antibody was generated in collaboration with England Enzo
Life Sciences UK (Palatine House, Matford Court, Exeter). The following antibodies were
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talso used: anti-HTT (MAB5490) and anti-HA.11 Clone 16B12 monoclonal (Covance); anti-
Myc 9E10 (Millipore); anti-EGFP detected by Living Colors Full-Length Monoclonal
Antibody (Clontech; JL-8); anti-mPIAS1 (Invitrogen); anti-SUMO-1 (Enzo Life Sciences);
anti-SUMO-2 (MBL International); and anti-ubiquitin (Santa Cruz Biotechnology).
GST Pull-Down Assays
Assays were performed as previously described (Steffan et al., 2000).
In Vitro SUMO Modification
The expression and purification of human E1 (SAE1/UBA2ΔCT), E2 (UBC9), IR1*
(RanBP2, aa 2,631–2,695), and mature SUMO-1 have been previously described (Bernier-
Villamor et al., 2002; Lois and Lima, 2005; Olsen et al., 2010; Reverter and Lima, 2005).
Mass Spectrometry
SUMO-1 T95R was generated by PCR mutagenesis (QuikChange Site-Directed
Mutagenesis Kit; Stratagene) to introduce a trypsin cleavage site near the SUMO C terminus
and purified as described for SUMO-1. Reactions containing 200 μM SUMO-1 T95R, 200
μM HTT (WT or S13,16D), 200 nM E1, 200 nM E2, and 2 μM IR1* in reaction buffer (20
mM HEPES [pH 7.5], 50 mM NaCl, 5 mM MgCl–2, 1 mM DTT, 1 mM ATP, and 0.01%
Tween 20) were incubated at 37ºC, and aliquots were removed at 0 and 60 min. Samples
were enriched by incubation with Ni-NTA beads (QIAGEN) and eluted with loading buffer
containing 100 mM EDTA. Samples were resolved by SDS-PAGE and stained with
Coomassie blue. Bands corresponding to HTT and SUMO-modified HTT were submitted
for analysis by mass spectrometry (Extended Experimental Procedures).
Cell Culture
HeLa cells were plated on 10 cm plates and cultured in DMEM plus 10% FBS. For cDNA
only, cells were plated on day 1 and transiently transfected with 6 μg of total DNA and 8 μl
Lipofectamine 2000 (Invitrogen) on day 2, media were changed on day 3, and cells were
collected on day 4. For siRNA only, transient transfections were carried out as described
above, except that 720 pmol siRNA and 36 μl of RNAi Max were used. For combined
siRNA and cDNA experiments, cells were transfected with siRNA, media were replaced on
day 2, and cDNA was transfected 12 hr after siRNA. Days 3 and 4 are as described above.
Cells were transfected at ~70% confluency for DNA and ~30%–50% confluency for siRNA.
Western Blot Analysis
A total of 8% bis-acrylamide gels and Invitrogen 4%–12% bis-tris mini gels were used for
SDS-PAGE, proteins were transferred to nitrocellulose membrane, and nonspecific proteins
were blocked with SuperBlock Blocking Buffer (Thermo Scientific). Two types of detection
were used: chemiluminescence/film, or Odyssey Imager/LI-COR (Extended Experimental
Procedures). Experiments were performed in triplicate with representative images shown.
Nickel Purifications
His-tagged HTT proteins were purified using magnetic Ni-NTA nickel beads (QIAGEN).
For in vitro SUMOylation assays, ST14.A cells were transfected with the 25QP-HBH
constructs into ~25 10 cm plates per construct and purified under native conditions using the
recommended buffers from QIAGEN (lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 10
mM imidazole, 0.05% Tween 20 [pH 8]; wash buffer: 50 mM NaH2PO4, 300 mM NaCl, 20
mM imidazole, 0.05% Tween 20 [pH 8]). For denaturing SUMO cell culture assay, HeLa
cells were transfected and purified under denaturing conditions using the recommended
buffer from QIAGEN (lysis buffer: 6 M guanidine HCl, 0.1 M NaH2PO4, 10 mM Tris-Cl
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t[pH 8]; Wash Buffer #1: 8 M urea, 100 mM NaH2PO4, 10 mM Tris-Cl [pH 8]; and Wash
buffer #2: 8 M urea, 100 mM NaH2PO4, 10 mM Tris-Cl [pH 6.3]). Of each lysate, 10% was
subjected to TCA precipitation. For the nickel purification, 50 μl of magnetic bead slurry
was added to each sample and incubated at room temperature for 3 hr. Beads were collected
on the magnetic rack, washed two times with Wash Buffer #1 (8 M urea [pH 8]), one time
with Wash Buffer #2 (8 M urea [pH 6.3]), and one final time with 1× PBS. Washed beads
were submerged in 2× Laemmli sample buffer, boiled for 10 min, and analyzed using
western analysis. Each experiment was performed in triplicate, and a representative figure is
shown.
Immunoprecipitations
HeLa cells were lysed in buffer containing 50 mM Tris-HCl [pH 8], 150 mM NaCl, 1%
NP40 alternative, a mini protease inhibitor pellet (Roche), 2 mM DTT, and 25 mM N-
ethylmaleimide (NEM) (Ulrich, 2009). HTT protein was either precipitated using protein G
plus from Santa Cruz or hydrazide-link beads from Bioclone.
Soluble/Insoluble Fractionation
HeLa cells were collected in lysis buffer containing 10 mM Tris (pH 7.4), 1% Triton X-100,
150 mM NaCl, 10% glycerol, and 0.2 mM PMSF (Roche Complete Protease Mini and
PhosphoStop pellets). Cells collected were lysed on ice for 60 min before centrifugation at
15,000 × g for 20 min at 4ºC. Supernatant was collected as the detergent-soluble fraction.
The pellet was washed 3× with lysis buffer and centrifuged at 15,000 × g for 5 min each at
4ºC. The pellet was resuspended in lysis buffer supplemented with 4% SDS, sonicated 3×,
boiled for 30 min, and collected as the detergent-insoluble fraction. Protein concentration
was quantitated using Lowry Protein Assay (Bio-Rad) Soluble/insoluble fractionation
protocol was previously described (Kim et al., 2011).
Filter Retardation Assay
A total of 30 μg of detergent-soluble and detergent-insoluble protein in 200 μl of 2% SDS
was boiled for 5 min and run through a dot blot apparatus under a vacuum onto a cellulose
acetate membrane. Membrane was then washed 3× with 0.1% SDS and then blocked in 5%
milk and subject to western blot analysis (previously described by Sontag et al., 2012;
Wanker et al. 1999).
RNA Isolation and Real-Time Quantitative PCR
Cortex and striatum were dissected from 4-, 8-, and 12-week-old female WT and R6/2 mice.
At King’s College London, hemizygous R6/2 mice were bred by backcrossing R6/2 males to
(CBA × C57BL/6) F1 females (B6CBAF1/ OlaHsd, Harlan Olac, Bicester) and maintained
as previously described by Labbadia et al. (2011). The CAG repeat was 204.7 ± 5.8. Brain
tissues were homogenized in TRIzol (Invitrogen), and total RNA was isolated using RNEasy
Mini kit (QIAGEN). DNase treatment was incorporated into the RNEasy procedure in order
to remove residual DNA. Reverse transcription was performed using oligo (dT) primers and
1 μg of total RNA using SuperScript III First-Strand Synthesis System (Invitrogen).
Quantitative PCR (qPCR) was performed (Table S1).
Automated Y2H Screening
GATEWAY technology (Invitrogen) was used to subclone 25Q-586 and 73Q-586 aa
cDNAs encoding human HTT fragments into Y2H expression plasmids. “Gateway
compatible” cDNAs encoding selected proteins were generated by PCR amplification.
Amplified DNA products were isolated from agarose gels and combined with the
pDONR221 plasmid (Invitrogen), creating the desired entry DNA plasmids. The identity of
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tall PCR products was verified by DNA sequencing. Subsequently, utilizing LR
recombination, pBTM116_D9 plasmids (for the production of LexA DNA-binding domain
fusions) were generated encoding HTT bait proteins for automated Y2H interaction mating.
The identity of the plasmids was verified by BsrGI restriction digestion. Bait plasmids were
transformed into the L40ccua MATa yeast strain, and yeast clones were individually mated
against a matrix of MATα yeast clones encoding 16,888 prey proteins (with Gal4 activation
domain fusions) using pipetting and spotting robots. The automated Y2H screenings were
repeated three times. Interaction mating experiments and imaging were performed as
described previously by Stelzl et al. (2005).
Drosophila Crosses
Flies were reared on standard cornmeal molasses medium at 25ºC. To compare phenotypes
of HTT-expressing animals in a normal versus a Su(var)2-10 (dPIAS)-reduced background,
w/w; +/+; UAS > HTTex1p-Q93/UAS > HTTex1p-Q93 females were crossed to elav-GAL4/
Y; Su(var)2-10[zimp-2]/ Sp males. Eclosion data from ≥1,500 segregants were calculated as
a percentage of elav-GAL4/+; Su(var)2-10/+ HTT/+ or elav-GAL4/+; +/Sp; HTT/+ flies
versus HTT-nonexpressing male siblings. Pseudopupil analysis was carried out on 7-day-old
flies as described (Steffan et al., 2001).
Human Postmortem Brain
Human autopsy brain tissue, from the striatum of control and patients with HD, was
obtained from individuals with ages at autopsy from 72 to 93 years of age and grades 3–4
and flash frozen with postmortem intervals ranging from 13 to 22 hr. Frozen human brain
tissue was homogenized on ice using T-PER Tissue Protein Extraction Reagent (Thermo
Scientific) containing a complete mini pellet (Roche), phosphatase inhibitor #1 (Sigma-
Aldrich), phosphatase inhibitor #2 (Sigma-Aldrich), and 25 mM NEM. Lysates were
ultracentrifuged at 45,000 rpm at 4ºC for 60 min, and the pellet was homogenized on ice in
70% formic acid, ultracentrifuged at 45,000 rpm at 4ºC for 60 min, and the supernatant was
collected as the “insoluble fraction.”
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. K6 and K9 Are Primary Sites for HTTex1p In Vitro SUMOylation
(A) Schematic illustration of the SUMOylation pathway. SUMO is expressed as a precursor
protein (SUMO-X) that is processed by SUMO-specific proteases (SENPs) to expose a C-
terminal diglycine motif (-GG). Enzymatic reactions are similar to ubiquitination and
include activation by the SUMO E1-activating enzyme (SAE1/UBA2), to the SUMO E2-
conjugating enzyme (Ubc9), and transfer of SUMO to target lysines with or without the
assistance of the SUMO E3-ligating enzymes.
(B) Time course of SUMO-1 modification of His-tagged HTTex1p (25Q)-purified proteins
(WT, K6R, K9R, K6,9R, K6,9,15R, and S13,16D) was performed in vitro. SUMOylation
was visualized using anti-His antibody. WT HTTex1p is SUMOylated within 16 min, K6R
or K9R mutations delay SUMOylation, and combined mutations (K6,9R or K6,9,15R)
greatly reduce SUMOylation. Mutations that mimic phosphorylation (S13,16D) alter
kinetics of SUMO-1 modification with SUMO modification observed beginning by 4 min.
See also Figure S1.
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tFigure 2. SUMO-1 and SUMO-2 Are Differentially Expressed in HD Mice versus Control
(A) qRT-PCR analysis of SUMO-modifying proteins and enzymes in cortex and striata of
WT mice at 12 weeks. Relative expression for all the SUMO enzymes is normalized to
mouse β-actin.
(B and C) qRT-PCR of SUMO mRNAs from 12-week-old WT and R6/2 mouse cortex (B)
and striatum (C). SUMO enzyme mRNAs are differentially expressed in R6/2 versus control
with statistically significant increases in SENP1 (p = 0.01), SENP3 (p = 0.02), and SUMO-1
(p = 0.003) in cortex and SENP1 (p = 0.02), SENP6 (p = 0.04), PIAS3 (p = 0.007), SUMO-1
(p = 0.02), and SUMO-2 (p = 0.02) in striatum. Samples were analyzed in quadruplicate and
normalized to mouse β-actin. Data are shown as R6/2 expression relative to WT levels set at
1 for each enzyme with ± SD (n = 4). *p < 0.05. n.s., not significant.
(D and E) Western blot analysis of SUMO-2 in 14-week R6/2 cortex (D) and striatum (E)
versus aged-matched controls. SUMO-2 is upregulated in R6/2 striatum versus control (p =
0.026; n = 4). Protein is normalized to α-tubulin and quantitated using ImageJ.
Note that only the 12-week time point is shown in (B) and (C). Please see 4- and 8-week
time points in Figures S2A and S2B.
O’Rourke et al. Page 19
Cell Rep. Author manuscript; available in PMC 2014 February 21.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 3. HTT Is Modified by Both SUMO-1 and SUMO-2
(A) HeLa cells transfected with His-tagged HTTex1p (46Q) or 46QP-K6,9,15R (3R) along
with GFP-SUMO-1 or GFP-SUMO-2, lysed under denaturing conditions, and nickel
purified (Ni-NTA). Unmodified HTT-46Q is indicated by the arrow and SUMO-modified
HTT by the boxed region. The lysine mutant (3R) serves as a negative control. Ni-NTA
represents nickel-purified His-tagged HTT, and WC TCA represents 10% of the whole-cell
lysate expression of HTT and myc-actin (transfection control). HTT is modified by
SUMO-1 (left) and SUMO-2 (right).
(B) SUMO isopeptidases (SENP1, SENP2, SENP3, SENP5, and SENP6) modulate SUMO-
modified HTT when overexpressed together with HTT (46QP-H4 or 3R) and SUMO-1
(GFP-SUMO-1). SENP1, SENP2, and SENP6 decrease HTT SUMOylation. Graph depicts
quantitation of western blot using the Odyssey Infrared Imaging System (LI-COR) to
calculate the ratio of HTT purified versus the HTT modified by SUMO multiplied by 100.
(C) Titration of SUMO-1. Denaturing nickel purification of HTTex1p (46QP-H4) following
transfection with decreasing amounts of SUMO-1 reduces the amount of SUMO-modified
HTT to undetectable levels. The Ni-NTA blot displayed in the gray scale shows purified
HTTex1 and SUMO-modified HTTex1 using HTT antibody. Note that 0.5 μg of SUMO-1
(¼ the amount of SUMO-1 cDNA ) was used for identifying the SUMO-1 E3 ligase for
HTTex1p. Graph depicts quantitation of western blot using the Odyssey Infrared Imaging
System to calculate the ratio of HTT purified versus the HTT modified by SUMO multiplied
by 100. Note that all experiments were performed in triplicate, and a representative figure is
shown.
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tFigure 4. PIAS1 Is a SUMO E3 Ligase for HTT
(A) Under limiting SUMO conditions (1/4 SUMO-1, lanes 3–9), PIAS1 increases HTT-
SUMO modification above 1/4 SUMO alone. Purified HTT (arrow) and SUMO-HTT
(boxed region) were detected using anti-HTT. Graph depicts quantitation of the Ni-NTA
western blot using the Odyssey Infrared Imaging Software (LI-COR) to calculate the ratio of
HTT purified versus the HTT modified by SUMO multiplied by 100.
(B) Western analysis of overexpression of HTTex1 (46QP-H4 or 3R), SUMO-2 (GFP-
SUMO-2), and all the PIAS proteins (PIAS1, PIASxα, PIASxβ, PIAS3, and PIASy). Under
nonlimiting SUMO-2 conditions, PIAS1 enhances SUMO modification of HTT. WC TCA
shows overall myc-actin (transfection control) and HTT levels. Graph quantitating the ratio
of HTT purified versus the HTT modified using the Odyssey (LICOR).
(C) Left panel is the autoradiography results of a GST pull-down assay showing that
radiolabeled human PIAS1 interacts with HTTex1p. Right panel is a phosphorimager
analysis of GST pull-downs, performed in triplicate, showing the percentage of 35S-labeled
PIAS protein that bound the GST proteins: GST alone, unexpanded HTT with and without
the proline-rich region (20QP and 20Q), expanded HTT with and without the proline-rich
region (51QP and 51Q), and the proline-rich region alone (Pro). Error bars were calculated
as an estimate of SE = STDEV(n)/SQRT(n-1).
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tFigure 5. A 586 aa Fragment of HTT Is SUMO Modified Downstream of Exon 1
(A) SUMOplot (Abgent) predicts that HTT is SUMOylated downstream of HTTex1p
lysines. SUMOplot analysis predicts two high-probability SUMO sites (red) and three low-
probability SUMO sites (blue) identified downstream of HTT exon 1. Greater than 13
overlapping noncovalent SIMs are observed within this fragment (yellow).
(B) Longer HTT polypeptides are modified by SUMO-1. Western blot overexpressing
HTTex1p (46QP-H4 or 3R), unexpanded HTT-586 fragment (25Q-586 or 25Q-3R-586 aa),
and expanded HTT-586 fragment (137Q-586 or 137Q-3R-586 aa) with SUMO-1 (GFP-
SUMO-1). Cell lysates were subjected to HTT immunoprecipitation (IP) using HTT
antibody. Western analysis performed with the Odyssey (LI-COR) allows detection of HTT
(data not shown) and SUMO simultaneously and shows that all forms of HTT are SUMO-1
modified using the anti-GFP antibody. HTTex1p is covalently SUMO-1 modified (lane 3),
and the modification disappears when Lys are mutated to Arg (3R) (lane 4). Both
unexpanded (lane 4 and 5) and expanded HTT-586 fragments (lane 6 and 7) are covalently
SUMO-1 modified in both the presence and absence of the three Lys in the N-terminal
region of HTT (3R). Free SUMO-1 is indicated with the arrow, and SUMO-modified HTT
is indicated by the boxes. Inset on the right, from a replicate experiment, shows comigration
of expanded HTT (anti-HTT) and SUMO-1 (anti-GFP) displayed in the gray scale and in
color when the two antibodies are merged (HTT in red, SUMO-1 in green, and yellow when
colocalizing).
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t(C) Bait plasmids (HTT-586-25Q or HTT-586-73Q aa) were transformed into the L40ccua
MATa yeast strain. Yeast clones encoding bait proteins were individually mated against a
matrix of MATα yeast clones encoding 16,888 prey proteins (with Gal4 activation domain
fusions) using pipetting and spotting robots. Diploid yeasts were spotted onto SDIV (-Leu-
Trp-Ura-His) agar plates for selection of PPIs as well as nylon membranes placed on SDIV
agar plates for β-galactosidase assays. After 5–6 days of incubation at 30ºC, digitized images
of the agar plates and nylon membranes were assessed for growth and β-galactosidase
activity using the software Visual Grid (GPC Biotech).
(D) Overexpression of PIAS1 alone, with unexpanded HTT constructs (25Q-586 aa) plus
SUMO-1 (GFP-SUMO-1), shows that PIAS1 binds both full-length HTT and HTT-586
fragment (25Q-586 aa). WT HTT was used in these experiments to preclude confounding
aggregation effects. Western analysis detection was performed using Odyssey and is
displayed in the gray scale but is shown in color on the merge (HTT is red, and PIAS1 is
green). WB, western blot.
(E) HeLa cells overexpressing either expanded 586 aa-HTT or the phosphomimetic
(S13,16D = DD) with SUMO-2 plus and minus PIAS1. HTT was purified by IP using
hydrazide beads (Bioclone) crosslinked to HTT (Enzo) antibody and subjected to western
analysis using anti-HTT (MAB5490). Arrows indicate SUMO-2-modified HTT.
(F) IP of HTT with hydrazide-linked beads shows that both unexpanded and expanded HTT
586 aa phosphomimetics (S13, 16D-586 aa) are modified by SUMO-2. Arrows indicate
SUMO-conjugated HTT. Note that all experiments including the Y2H assay were done in
triplicate; representative experiments are shown. Arrows indicate SUMO-2-modified HTT.
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tFigure 6. SUMO-2 Causes Mutant HTT to Accumulate
(A) Western analysis of whole-cell lysates from HeLa cells transfected with His-SUMO-1 or
SUMO-2 and/or 97Q-HTT exon 1 and treated with 5 μM MG132 for 18 hr. Lysates were
separated using differential centrifugation into a detergent-soluble fraction (SOLUBLE)
with 1% Triton X-100 and a detergent-insoluble fraction (INSOLUBLE) with 4% SDS.
Western blot probed with anti-HTT shows full-length endogenous HTT in the SOLUBLE
fraction (upper arrow) and 97Q-HTTex1 (lower arrow) (left panel). In the INSOLUBLE
fraction, HTT HMW species are indicated by the bracket and asterisks (right panel).
(B) MG132 and SUMO-2 cause mutant HTT to accumulate as HMW species (bracke and
asterisk). Western blot showing IP with HTT antibody crosslinked beads from the detergent-
insoluble fraction probed with the anti-HTT antibody.
(C) Mutant HTT (97Q-Httex1) fibrils are detected with anti-HTT in the insoluble fraction
with treatment of MG132 or addition of exogenous SUMO-2.
O’Rourke et al. Page 25
Cell Rep. Author manuscript; available in PMC 2014 February 21.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t(D) Western blot with increasing concentrations of SUMO-2 detected with anti-His antibody
(left panel). Middle panel is the same western blot probed with anti-HTT showing soluble
forms of HTT. Right panel presents western blot from detergent-insoluble fraction with
monomeric HTT (97Q) at 55 kDa, and the asterisk (*) indicates the HMW species. Note that
all experiments were performed in triplicate; representative figures are shown.
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tFigure 7. SUMO-2 Proteins Accumulate in HD Brain
(A) Western blot analysis of HeLa cells over-expressing exogenous PIAS1 in the presence
of mutant HTT (97Q) when separated into detergent-soluble and detergent-insoluble
fractions. No difference is detected in monomeric HTT (top panel, Soluble), but HMW HTT
levels increase with PIAS1 overexpression. Anti-PIAS1 antibody (Invitrogen) was used to
detect PIAS1.
(B) Acute knockdown of PIAS1 decreases HMW HTT species in the detergent-insoluble
fraction. PIAS1 knockdown is detected in detergent-soluble and -insoluble fractions using
anti-PIAS1 antibody.
(C) Drosophila melanogaster expressing mutant HTTex1p (93Q) in a reduced Su(var)2-10/
dPIAS genetic background exhibits statistically significantly reduced photoreceptor neuron
degeneration (left panel, p = 0.033) when comparing dPIAS/+ to +/+ flies and increased
overall survival (right panel, p = 0.047) when comparing dPIAS1/+ to +/+ flies. Significance
was measured by Student’s t test.
(D) HMW SUMO-2 accumulates in postmortem HD striata. Western blot analysis of the
insoluble fraction from three control and three HD postmortem striata as described
(Experimental Procedures).
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